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Objectives

30
To assess the impact of 5 or more cycles of neoadjuvant chemotherapy (NACT) and 31 cytoreductive outcomes on overall survival (OS) in patients undergoing interval debulking 32 surgery (IDS) for advanced ovarian cancer.
33
Methods
34
A retrospective review of patients receiving NACT followed by IDS between 2007-2017. 35 Patients were analysed according to number of NACT cycles received: group 1 consisted of 36 patients receiving ≤4 cycles and group 2 consisted of those receiving ≥5 cycles. Outcomes 37 were stratified by cytoreductive outcome, surgical complexity, stage and chemotherapy 38 exposure.
39
Results
40
231 patients in group 1 and 167 in group 2 were identified. In group 1, the OS for those 41 achieving Complete(R0), Optimal<1cm(R1) and Suboptimal(R2) was 51.1, 36.1, and 34.3 42 months respectively. Statistically significant differences in survival were seen in patients 43 achieving R0vR2(p<0.019) but not in R0vR1(p=0.125) or R1vR2(p=0.358). In group 2, the 44 OS for those achieving R0, R1 and R2 was 53.0, 24.7, and 22.1 months respectively.
45
Statistically significant differences were seen between R0vR1 and R0vR2 (p<0.00001) but 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 3 Surgery with utilisation of cytoreductive procedures to achieve complete clearance should be 52 offered to all patients even after ≥5 cycles if R0 can be achieved. R1 cytoreduction has 53 questionable value in those receiving ≤4 cycles and no value in those receiving ≥5 cycles. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 INTRODUCTION   59 Cancer of the fallopian tube, ovary or peritoneum (epithelial ovarian cancer) is the second 60 most common and the most lethal gynaecological malignancy (1). The foundation for the 61 modern management of this condition is the utilisation of surgery with the intention to 62 remove all macroscopic disease (2-4) and platinum and taxane-based chemotherapy, either as 63 treatment following surgery (adjuvant) or as treatment both before and after surgery (neo-64 adjuvant, NACT). Since the publication of two randomised controlled trials demonstrating 65 non-inferiority of NACT over primary surgery (5, 6) the rates of NACT usage have 66 increased, in the US, overall to 22.6%(7) with some centres using NACT in up to 34% of 
137
Data Collection
138
The following data items were collected: age at initial diagnosis; body mass index (BMI);
139
FIGO stage; histological sub-type and grade; level of cytoreduction achieved (R0, R1 and R2
140
(sub-optimal)); surgical complexity score (low, intermediate and high (24) that study was 41.9 months and we postulate that the slightly lower OS may be due to that 269 study not giving adjuvant chemotherapy to those patients receiving IDS after 6 cycles. (17).
270
We postulate that there may be a survival benefit despite concerns about toxicity from some 271 consolidation adjuvant chemotherapy (in our centre 2-3 cycles) even after extensive exposure 272 to NACT. We suggest therefore that establishing the value of consolidation chemotherapy 273 following IDS after extended NACT cycles is a trial worthy of consideration. 5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65   11   275 One of the limitations of our study is the lack of accurate initial disease distribution data. whether the use of an extra cycle of NACT to facilitate timing of surgery can be justified . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 12
Despite concerns regarding the value of R1 cytoreduction in IDS, our data shows that if more 308 than 4 cycles are needed for patient or disease factors it can be used with no adverse effects 309 providing that R0 is achieved. Table 3 : Median OS of all patients analysed by cytoreductive outcomes and NACT exposure. Table3   Tables/Figures   Table 1 
